ESR1 and breast cancer: Cost-effective but less accurate immunohistochemical and in situ hybridization methods allow systematic categorization of breast cancer into estrogen receptor-positive (ER+) luminal, HER2-positive, and triple-negative subtypes, reflecting the type of adjuvant therapy in the clinics [27].